Journal article icon

Journal article

3,4-Diaminopyridine in the treatment of congenital (hereditary) myasthenia.

Abstract:

Congenital or hereditary myasthenia describes a heterogeneous group of disorders in which the immune system is not implicated. Treatment has previously depended on anticholinesterase medication. The effectiveness of 3,4-diaminopyridine (3,4-DAP), a preparation that enhances acetylcholine release from motor nerve terminals, has been evaluated using a series of standardised strength measures. Sixteen patients (aged seven to 47 years) were studied in an open prospective trial, and four of them i...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1136/jnnp.54.12.1069

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Clinical Neurosciences
Role:
Author
Journal:
Journal of neurology, neurosurgery, and psychiatry More from this journal
Volume:
54
Issue:
12
Pages:
1069-1072
Publication date:
1991-12-01
DOI:
EISSN:
1468-330X
ISSN:
0022-3050
Language:
English
Keywords:
Pubs id:
pubs:387064
UUID:
uuid:672e6f78-445e-4da3-b8ab-b15338783859
Local pid:
pubs:387064
Source identifiers:
387064
Deposit date:
2013-11-16

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP